Maxim Group set a $8.00 price target on Viking Therapeutics (NASDAQ:VKTX) in a research report sent to investors on Tuesday. The brokerage currently has a buy rating on the biotechnology company’s stock.

A number of other research analysts have also recently issued reports on the stock. HC Wainwright reaffirmed a buy rating and issued a $7.00 target price on shares of Viking Therapeutics in a report on Friday, November 10th. Roth Capital initiated coverage on shares of Viking Therapeutics in a report on Tuesday, November 21st. They issued a buy rating and a $5.00 target price for the company. Finally, ValuEngine cut shares of Viking Therapeutics from a hold rating to a sell rating in a report on Friday, December 1st.

Viking Therapeutics (NASDAQ VKTX) opened at $3.89 on Tuesday. Viking Therapeutics has a 1-year low of $0.88 and a 1-year high of $4.28.

Viking Therapeutics (NASDAQ:VKTX) last issued its earnings results on Wednesday, November 8th. The biotechnology company reported ($0.22) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.19) by ($0.03). sell-side analysts forecast that Viking Therapeutics will post -0.86 earnings per share for the current fiscal year.

Institutional investors have recently modified their holdings of the business. Citadel Advisors LLC purchased a new position in shares of Viking Therapeutics during the 3rd quarter worth approximately $108,000. Sphera Funds Management LTD. purchased a new position in shares of Viking Therapeutics during the 3rd quarter worth approximately $554,000. Sabby Management LLC purchased a new position in shares of Viking Therapeutics during the 2nd quarter worth approximately $525,000. Virtu KCG Holdings LLC purchased a new position in shares of Viking Therapeutics during the 2nd quarter worth approximately $124,000. Finally, Renaissance Technologies LLC increased its stake in shares of Viking Therapeutics by 62.9% during the 1st quarter. Renaissance Technologies LLC now owns 265,800 shares of the biotechnology company’s stock worth $388,000 after purchasing an additional 102,600 shares in the last quarter. 7.40% of the stock is owned by institutional investors.

TRADEMARK VIOLATION WARNING: “Viking Therapeutics (VKTX) Given a $8.00 Price Target at Maxim Group” was originally reported by Watch List News and is owned by of Watch List News. If you are viewing this piece of content on another publication, it was stolen and republished in violation of United States & international trademark & copyright legislation. The legal version of this piece of content can be read at https://www.watchlistnews.com/viking-therapeutics-vktx-given-a-8-00-price-target-at-maxim-group/1761055.html.

Viking Therapeutics Company Profile

Viking Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company focuses on the development of therapies for metabolic and endocrine disorders. The Company’s clinical program, VK5211, is an orally available drug candidate, which is in Phase II clinical trial for acute rehabilitation following non-elective hip fracture surgery.

Receive News & Ratings for Viking Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Viking Therapeutics and related companies with Analyst Ratings Network's FREE daily email newsletter.